Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Future Virol ; 2023 Jan.
Article in English | MEDLINE | ID: mdl-36844192

ABSTRACT

Aim: More data is required regarding the association between HLA allele and red blood cell (RBC) antigen expression in regard to SARS-CoV-2 infection and COVID-19 susceptibility. Methods: ABO, RhD, 37 other RBC antigens and HLA-A, B, C, DRB1, DQB1 and DPB1 were determined using high throughput platforms in 90 Caucasian convalescent plasma donors. Results: The AB group was significantly increased (1.5×, p = 0.018) and some HLA alleles were found to be significantly overrepresented (HLA-B*44:02, C*05:01, DPB1*04:01, DRB1*04:01 and DRB1*07:01) or underrepresented (A*01:01, B51:01 and DPB1*04:02) in convalescent individuals compared with the local bone marrow registry population. Conclusion: Our study of infection-susceptible but non-hospitalized Caucasian COVID-19 patients contributes to the global understanding of host genetic factors associated with SARS-CoV-2 infection and severity.

2.
Transfusion ; 61(9): 2727-2735, 2021 09.
Article in English | MEDLINE | ID: mdl-34121202

ABSTRACT

BACKGROUND: The determination of the RhD phenotype is crucial to avoid alloimmunization, especially in childbearing women. Following the 2015 recommendation from the Work Group on RHD Genotyping, a large-scale RHD genotyping program was implemented in the province of Quebec (Canada) and offered to women ≤45 years old with a serological weak D or discordant results. Since weak D type 42 was previously shown to be prevalent among French Canadians, genotyping for that variant was also performed. Our aim was to report the prevalence of the weak D alleles in the province of Quebec. STUDY DESIGN AND METHODS: A retrospective study of 2105 women with serological weak D referred to Hema-Quebec's immunohematology reference laboratory (IRL) between June 2016 and May 2020 was conducted. Results from the serological tests performed by the referring hospital were compiled and RHD were genotyped. RESULTS: Most patients presented at least one serological result ≤2+ before being referred to Hema-Quebec. Weak D type 42 was the most prevalent variant, representing 17.5% (368/2105) of all individuals tested. Only 15.3% (323/2105) of patients were weak D type 1, 3.3% (69/2105) were type 2, and 8.6% (180/2105) were type 3. Weak D type 42 is highly expressed in regions with low immigration rate and known for their founder effect. CONCLUSION: Our RHD genotyping program allowed for a better management of weak D. The province of Quebec presents a unique RHD genotype distribution. We confirmed that weak D type 42 is associated with a founder effect found in Caucasian French Canadians.


Subject(s)
Rh-Hr Blood-Group System/genetics , Adult , Alleles , Female , Genetic Variation , Genotype , Humans , Prevalence , Quebec , RNA, Messenger/genetics , Retrospective Studies , Young Adult
3.
Transfusion ; 61(5): 1489-1494, 2021 05.
Article in English | MEDLINE | ID: mdl-33515215

ABSTRACT

BACKGROUND: A global downtrend in blood usage has been observed by many countries, while the demand for antigen-negative red blood cell (RBC) units used in antigen-matched transfusions keeps increasing. The declining number of units collected exposes blood providers to a rapidly evolving supply challenge. METHODS: This study was conducted retrospectively with use of internal data analysis to weigh Québec's situation regarding global and antigen-negative RBC demand, to measure the effects of community-directed recruitment and blood drives, and to evaluate the benefits of mass-scale RBC genotyping. RESULTS: Our findings confirm a global RBC usage downtrend of over 20% total in the past 10 years with a steady antigen-negative usage and highlight the most requested negative antigen combinations. Our data also show our +39.5% progress regarding the number of Black donors recruited for antigen matching of patients with sickle cell disease in the past 3 years, as well as a constantly growing number of just-in-time blood collection for complex orders. Finally, our data summarize the efficiency of our mass-scale RBC genotyping efforts. CONCLUSION: Altogether, this study confirms the demand trends for regular and antigen-negative RBC units in Québec and the efficient effects of our recruitment and typing strategies.


Subject(s)
Blood Group Antigens/blood , Donor Selection , Erythrocyte Transfusion , Blood Grouping and Crossmatching , Donor Selection/methods , Erythrocyte Transfusion/methods , Humans , Retrospective Studies , Tissue Donors
4.
Transfusion ; 47(10): 1794-802, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17880603

ABSTRACT

BACKGROUND: Hepatitis B virus (HBV) infection can be detected in blood donations by many serologic markers. Since the introduction of routine anti-hepatitis B core antigen (HBc) donor screening at Héma-Québec in April 2003, a large number of donors have been deferred on the basis of reactive anti-HBc test results. The objective of this study was to evaluate the correlation between the anti-HBc-reactive donations and the detection of HBV DNA with an in-house nucleic acid testing (NAT) assay. STUDY DESIGN AND METHODS: The in-house HBV NAT assay is a conventional polymerase chain reaction amplifying part of the viral S gene. From October 2004 to November 2005, a total of 1169 anti-HBc-reactive donations were tested with this in-house assay. The results were correlated with hepatitis B surface antigen (HBsAg) and anti-HBs markers. HBV DNA-positive samples were further investigated by DNA sequencing. RESULTS: All HBsAg-positive samples were detected by the NAT assay. Overall, 38 (3.25%) of anti-HBc-positive samples were found to be positive for the presence of HBV DNA. Of these 38, a total of 12 donations with a low level of HBV DNA were HBsAg-negative. The sequencing results clearly showed various genotypes and subtypes within a same genotype. CONCLUSION: The 3.25 percent HBV DNA positivity rate among the anti-HBc-reactive donations and more particularly the low level of HBV DNA observed in occult donations underline the importance of the use of a sensitive assay to detect HBV DNA in conjunction with other markers. The HBV genetic diversity found in our donor population reflects the province demographics, particularly in the Montreal area where most of the positive donors were from.


Subject(s)
Blood Donors/statistics & numerical data , Blood Transfusion/standards , Hepatitis B Antigens/blood , Hepatitis B virus/isolation & purification , Amino Acid Sequence , Blood Specimen Collection/methods , DNA Primers , DNA, Viral/blood , DNA, Viral/isolation & purification , Genotype , Hepatitis B virus/classification , Hepatitis B virus/genetics , Humans , Molecular Sequence Data , Phylogeny , Polymerase Chain Reaction/methods , Quebec , RNA, Viral/blood
5.
Transfusion ; 46(12): 2115-21, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17176323

ABSTRACT

BACKGROUND: Transfusion of blood products to immunoglobulin A (IgA)-deficient patients who have developed IgA antibodies can result in serious adverse reactions. To prepare compatible blood components for these patients, blood centers usually maintain a list of IgA-deficient blood donors. An in-house enzyme-linked immunosorbent assay (ELISA) was used to identify new IgA-deficient blood donors. STUDY DESIGN AND METHODS: An in-house ELISA was used to screen blood samples. IgA-deficient samples, defined as an IgA level below 0.05 mg per dL, were sent to the American Red Cross for confirmatory testing. RESULTS: Seventy-three confirmed IgA-deficient blood donors were identified among 38,759 screened blood donor samples (frequency, 1:531). IgA antibodies were found in 39 of these 73 blood donors (53%), although only 9 donors had a history of adult IgA exposure (transfusion or pregnancy). CONCLUSIONS: With a simple in-house ELISA, 73 blood donors were identified as IgA-deficient. From this number, 34 donors, without detectable anti-IgA in their plasma, were added to our IgA-deficient blood donor panel to maximize the management of our inventory of IgA-deficient frozen blood components.


Subject(s)
Blood Donors , Enzyme-Linked Immunosorbent Assay/methods , IgA Deficiency/blood , Registries , Antibodies, Anti-Idiotypic/blood , Humans
6.
Hybrid Hybridomics ; 23(6): 362-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15684663

ABSTRACT

Enzyme-antibody (Ab) conjugates specific for IgG are widely used in indirect immunological assays and have been until recently routinely prepared with polyclonal IgG-specific animal Abs. The use of monoclonal Abs (MAbs) could permit a better standardization of the IgG-specific conjugate reagents but is expected to result in lower reactivity due to the recognition of a single epitope by the MAbs. In this work, we have characterized a monoclonal anti-human IgG-peroxidase (HRP) reagent and compared its reactivity with commercial reagents. The murine C5-1 anti-human IgG MAb was selected for conjugation because of its high affinity (K(a) = 1.9 x 10(10)M), pan-IgG reactivity and absence of cross-reactivity with various structures including animal IgGs. The specific activity and binding kinetics of the C5-1:HRP conjugate were similar to the ones of two polyclonal anti-IgG:HRP conjugates when tested with immobilized human IgG. The C5-1:HRP conjugate could detect low amounts of human IgG much more effectively than two commercial monoclonal conjugates although it was slightly less effective than a polyclonal conjugate. However, the C5-1 conjugate yielded reduced background reactivity compared to the polyclonal conjugate, resulting in similar signal-to-noise ratios. These results indicate that the C5-1:HRP conjugate could be a suitable substitute for anti-human IgG conjugates prepared from animal antisera.


Subject(s)
Antibodies, Monoclonal/immunology , Enzyme-Linked Immunosorbent Assay/methods , Immunoglobulin G/analysis , Peroxidase/immunology , Animals , Humans , Immunoglobulin G/immunology , Kinetics , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...